ESA Chair Prof. Giamarellos to Present Landmark IMMUNOSEP Trial at CCR Down Under 2025
The European Sepsis Alliance is proud to celebrate the upcoming participation of our Chair, Prof. Evangelos J. Giamarellos-Bourboulis, at CCR Down Under 2025 taking place on 9–10 December in Melbourne, Australia. His invitation to present the pioneering IMMUNOSEP trial marks a remarkable recognition of European leadership in sepsis research and innovation.
CCR Down Under is widely regarded as one of the most authoritative global forums in intensive care medicine, known for unveiling the most influential multicentre clinical trials that shape clinical practice and inform international guidelines. Being selected among the top eight critical care trials worldwide is a distinction that reflects both the scientific excellence of the work and its potential to transform patient care.
“Being selected for CCR Down Under is not just an honor. It is a statement about the global relevance of our research. […] Our mission is to generate evidence that does more than inform practice, it transforms it.”
IMMUNOSEP, conducted across six European countries over nearly three years, is a groundbreaking clinical study exploring a personalised immunotherapy strategy for sepsis. Instead of treating sepsis as a uniform condition, the trial evaluates targeted treatments based on each patient’s immune profile. This approach recognises that sepsis patients can experience vastly different immune responses—some develop overwhelming inflammation, whereas others suffer from immune paralysis. By tailoring treatment to the individual, IMMUNOSEP aims to improve survival, reduce complications, and ultimately change the way sepsis is treated worldwide.
If confirmed in broader clinical practice, the trial’s findings could open the door to a new era of precision medicine in sepsis, allowing clinicians to intervene earlier, more effectively, and with therapies selected to match the underlying immune dysfunction. Such innovation has the potential to save thousands of lives every year and reduce the enormous global burden of sepsis.
The invitation to present IMMUNOSEP at CCR Down Under represents an important milestone not only for Prof. Giamarellos and the other partners of the trial, including ESA Steering Committe members Prof. Michael Bauer and Prof. Joost Wiersinga, but for the entire European sepsis research community. As he noted, this recognition highlights the growing global relevance of European science and its contribution to the future of critical care.
The presentation will be freely accessible via livestream on the CCR website on Tuesday 9, as of 9:00 AEDT (Monday 8, 23:00 CET).